Trials / Completed
CompletedNCT01508364
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
NEXTAR - NEXavar® as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY 43-9006) | Dosage according to label or at discretion of the attending physician |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2012-01-12
- Last updated
- 2015-01-21
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01508364. Inclusion in this directory is not an endorsement.